Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Maintenance in Advanced Marginal Zone B-cell Lymphoma
NCT01213095Phase 2Completed
- Start
- Sep 2010
- Primary completion
- Sep 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in marginal zone B-cell lymphoma (MZL). Started Sep 2010; status: completed.
02
Drugs
rituximab
03
Conditions
marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on NCT01213095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01213095.